AMRX · Amneal Pharmaceuticals, Inc.
$18.15
+0.88 (+5.10%)
At close · Aug 14
Market Cap
$5.80B
Shares
319.35M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$18.15
Open$17.07
Day$16.87–18.17
52W close$9.26–19.10
Avg vol 30d1.9M
Short int8.3M · 2.6% float · 4.6d
Short vol64%
Last earningsJul 30, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Oct 26, 2026
Est · unconfirmed
· in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bearish
Fundamentals
Strong
Quant / Vol
Moderate
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+31%
above
Price vs 50-day avg
+6%
above
RSI (14)
55
neutral
MACD trend
Negative
52-week position
90%
near high
Momentum
relative strength
1-month return
+2%
trailing
6-month return
+26%
trailing
YTD return
+44%
this year
Relative strength
+12%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $17 › 200d $14 — 50d above 200d
Institutional flow
Distributing
-4% holders QoQ · +46 funds added
Insider flow
Distributing
Net -$7.2M over 90 days · 100% sells
Short interest
Rising
2.61% of float · ▲ +2.5% MoM · 4.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
304 holders — mid 3-yr range
Squeeze score
64
elevated · 0–100
Fundamentals
Revenue growth
+8%
Y/Y
Gross margin
37%
expanding
EPS growth
+158%
Y/Y
Free cash flow
$269.9M
Valuation
P/E 37.8
rich
Balance sheet
$2.3B
net debt
Quant / Vol
risk profile
Volatility
34%
annualized · 1-yr
Max drawdown
−22%
past year
ATR
3.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Jul 30, 2026
Net revenue
· full year 2026
$3.1B – $3.2B
Adjusted EBITDA
· full year 2026
Non-GAAP
$750M – $780M
Adjusted diluted EPS
· full year 2026
Non-GAAP
$0.96 – $1.06
Operating cash flow
· full year 2026
$350M – $400M
Operating cash flow, excluding discrete items
· full year 2026
Non-GAAP
$375M – $425M
Capital expenditures
· full year 2026
$150M
Prior guidance
period ended
· from the 8-K filed Jan 13, 2026
Net revenue
· 2025 full-year
$3B – $3.1B
Adjusted EBITDA
· 2025 full-year
$675M – $685M
Guided vs delivered
· last 1 settled
Total net revenue
full-year
guided $2.55B – $2.65B
$2.79B
Beat +7.5%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+31%
Bullish
Price vs 50-day avg
+6%
Bullish
RSI (14)
55
Neutral
MACD trend
Negative
Bearish
52-week position
90%
Bullish
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
No cross
50d $17 › 200d $14 — 50d above 200d
Institutional flow
Distributing
-4% holders QoQ · +46 funds added
Insider flow
Distributing
Net -$7.2M over 90 days · 100% sells
Short interest
Rising
2.61% of float · ▲ +2.5% MoM · 4.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
304 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $9
Now $18 · 90%
Range high $19
vs 200-day avg +31%
vs 50-day avg +6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $206M | second quarter of 2026 | — |
|
|
|||
| Adjusted diluted EPS non-GAAP | $0.27 | Q1 2026 | — |
|
|
|||
| Adjusted Net Income non-GAAP | $269M | Full Year 2025 | — |
| Net leverage non-GAAP | 3.6 | FY2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AMRX
this stock
Amneal Pharmaceuticals, Inc.
|
$5.80B | +44.0% | +8.0% | 37.8 | 2.6% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$64.91B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$56.30B | +13.1% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$49.59B | +2.4% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$42.85B | +17.8% | +4.3% | 60.3 | 2.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AMRX | +0.1% | +1.7% | +25.9% | -0.9% | +44.1% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -0.3% | -2.8% | +12.1% | -4.9% | +30.2% |
Key facts
CIK
1723128
CUSIP
03168L105
13F (30d)
292 filings
288 filers
Visit website
Investor relations